CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer

Irinotecan specifically targets topoisomerase I (topoI), and is used to treat various solid tumors, but only 13–32% of patients respond to the therapy. Now, it is understood that the rapid rate of topoI degradation in response to irinotecan causes irinotecan resistance. We have published that the de...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsuoka, Hiroya, Ando, Koji, Swayze, Emma J., Unan, Elizabeth C., Mathew, Joseph, Hu, Quingjiang, Tsuda, Yasuo, Nakashima, Yuichiro, Saeki, Hiroshi, Oki, Eiji, Bharti, Ajit K., Mori, Masaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413750/
https://www.ncbi.nlm.nih.gov/pubmed/32764831
http://dx.doi.org/10.1371/journal.pone.0228002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413750/
https://www.ncbi.nlm.nih.gov/pubmed/32764831
http://dx.doi.org/10.1371/journal.pone.0228002

Ejemplares similares